MedTrace Logo

Desmopressin for Bleeding Related to Low Body Temperature

NCT00902057 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-05-14

No results posted yet for this study

Summary

To study, with a prospective randomised controlled design, whether the subcutaneous administration of the haemostatic drug desmopressin, may improve the impairment of primary haemostasis due to mildly decreased temperature.

Conditions

  • Hypothermia Induced Impairment of Primary Haemostasis

Interventions

DRUG

desmopressin

single desmopressin subcutaneous injection, 1.5mcg

DRUG

desmopressin

single desmopressin subcutaneous injection, 3mcg

DRUG

desmopressin

single desmopressin subcutaneous injection, 15mcg

DRUG

placebo

saline subcutaneous

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-12-31
Completion
2011-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902057 on ClinicalTrials.gov